30 Years of Biotherapeutics Development-What Have We Learned?

被引：16

作者：

Ghilardi, Nico ^{[1
]}

Pappu, Rajita ^{[1
]}

Arron, Joseph R. ^{[1
]}

Chan, Andrew C. ^{[2
]}

机构：

[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA

[2] Genentech Inc, Res Biol, San Francisco, CA 94080 USA

来源：

ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 | 2020年 / 38卷

关键词：

biotherapeutics; autoimmunity; inflammation; clinical trial; TUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; B-CELL DEPLETION; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; SEVERE ASTHMA; PHASE-III; FACTOR-ALPHA;

D O I：

10.1146/annurev-immunol-101619-031510

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Since the birth of biotechnology, hundreds of biotherapeutics have been developed and approved by the US Food and Drug Administration (FDA) for human use. These novel medicines not only bring significant benefit to patients but also represent precision tools to interrogate human disease biology. Accordingly, much has been learned from the successes and failures of hundreds of high-quality clinical trials. In this review, we discuss general and broadly applicable themes that have emerged from this collective experience. We base our discussion on insights gained from exploring some of the most important target classes, including interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-alpha), IL-6, IL-12/23, IL-17, IL-4/13, IL-5, immunoglobulin E (IgE), integrins and B cells. We also describe current challenges and speculate about how emerging technological capabilities may enable the discovery and development of the next generation of biotherapeutics.

引用

页码：249 / 287

页数：39

共 232 条

[81] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials [J].

Griffiths, Christopher E. M. ;

Reich, Kristian ;

Lebwohl, Mark ;

van de Kerkhof, Peter ;

Paul, Carle ;

Menter, Alan ;

Cameron, Gregory S. ;

Erickson, Janelle ;

Zhang, Lu ;

Secrest, Roberta J. ;

Ball, Susan ;

Braun, Daniel K. ;

Osuntokun, Olawale O. ;

Heffernan, Michael P. ;

Nickoloff, Brian J. ;

Papp, Kim .

LANCET, 2015, 386 (9993) :541-551

[82] Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis [J].

Griffiths, Christopher E. M. ;

Strober, Bruce E. ;

van de Kerkhof, Peter ;

Ho, Vincent ;

Fidelus-Gort, Roseanne ;

Yeilding, Newman ;

Guzzo, Cynthia ;

Xia, Yichuan ;

Zhou, Bei ;

Li, Shu ;

Dooley, Lisa T. ;

Goldstein, Neil H. ;

Menter, Alan .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (02) :118-128

[83] Immunity, Inflammation, and Cancer [J].

Grivennikov, Sergei I. ;

Greten, Florian R. ;

Karin, Michael .

CELL, 2010, 140 (06) :883-899

[84] A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains [J].

Haddick, Patrick C. G. ;

Larson, Jessica L. ;

Rathore, Nisha ;

Bhangale, Tushar R. ;

Phung, Qui T. ;

Srinivasan, Karpagam ;

Hansen, David V. ;

Lill, Jennie R. ;

Pericak-Vance, Margaret A. ;

Haines, Jonathan ;

Farrer, Lindsay A. ;

Kauwe, John S. ;

Schellenberg, Gerard D. ;

Cruchaga, Carlos ;

Goate, Alison M. ;

Behrens, Timothy W. ;

Watts, Ryan J. ;

Graham, Robert R. ;

Kaminker, Joshua S. ;

van der Brug, Marcel .

JOURNAL OF ALZHEIMERS DISEASE, 2017, 56 (03) :1037-1054

[85] Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma [J].

Haldar, Pranabashis ;

Brightling, Christopher E. ;

Hargadon, Beverley ;

Gupta, Sumit ;

Monteiro, William ;

Sousa, Ana ;

Marshall, Richard P. ;

Bradding, Peter ;

Green, Ruth H. ;

Wardlaw, Andrew J. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (10) :973-984

[86] Plasma cell survival in the absence of B cell memory [J].

Hammarlund, Erika ;

Thomas, Archana ;

Amanna, Ian J. ;

Holden, Lindsay A. ;

Slayden, Ov D. ;

Park, Byung ;

Gao, Lina ;

Slifka, Mark K. .

NATURE COMMUNICATIONS, 2017, 8

[87] Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials [J].

Hanania, Nicola A. ;

Korenblat, Phillip ;

Chapman, Kenneth R. ;

Bateman, Eric D. ;

Kopecky, Petr ;

Paggiaro, Pierluigi ;

Yokoyama, Akihito ;

Olsson, Julie ;

Gray, Sarah ;

Holweg, Cecile T. J. ;

Eisner, Mark ;

Asare, Charles ;

Fischer, Saloumeh K. ;

Peng, Kun ;

Putnam, Wendy S. ;

Matthews, John G. .

LANCET RESPIRATORY MEDICINE, 2016, 4 (10) :781-796

[88] Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies [J].

Hanania, Nicola A. ;

Noonan, Michael ;

Corren, Jonathan ;

Korenblat, Phillip ;

Zheng, Yanan ;

Fischer, Saloumeh K. ;

Cheu, Melissa ;

Putnam, Wendy S. ;

Murray, Elaine ;

Scheerens, Heleen ;

Holweg, Cecile T. J. ;

Maciuca, Romeo ;

Gray, Sarah ;

Doyle, Ramona ;

McClintock, Dana ;

Olsson, Julie ;

Matthews, John G. ;

Yen, Karl .

THORAX, 2015, 70 (08) :748-756

[89] Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study [J].

Hanania, Nicola A. ;

Wenzel, Sally ;

Rosen, Karin ;

Hsieh, Hsin-Ju ;

Mosesova, Sofia ;

Choy, David F. ;

Lal, Preeti ;

Arron, Joseph R. ;

Harris, Jeffrey M. ;

Busse, William .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (08) :804-811

[90] A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma [J].

Harris, Jeffrey M. ;

Maciuca, Romeo ;

Bradley, Mary S. ;

Cabanski, Christopher R. ;

Scheerens, Heleen ;

Lim, Jeremy ;

Cai, Fang ;

Kishnani, Mona ;

Liao, X. Charlene ;

Samineni, Divya ;

Zhu, Rui ;

Cochran, Colette ;

Soong, Weily ;

Diaz, Joseph D. ;

Perin, Patrick ;

Tsukayama, Miguel ;

Dimov, Dimo ;

Agache, Ioana ;

Kelsen, Steven G. .

RESPIRATORY RESEARCH, 2016, 17

← 4 5 6 7 8 9 10 11 12 13 →